Last reviewed · How we verify
Vilazodone; Viibryd
Vilazodone inhibits serotonin reuptake and acts as a partial agonist at the serotonin 5-HT1A receptor to treat depression.
Vilazodone inhibits serotonin reuptake and acts as a partial agonist at the serotonin 5-HT1A receptor to treat depression. Used for Major depressive disorder.
At a glance
| Generic name | Vilazodone; Viibryd |
|---|---|
| Also known as | Vilazodone, Viibryd, Antidepressant |
| Sponsor | University of California, Los Angeles |
| Drug class | SSRI with 5-HT1A partial agonist activity |
| Target | Serotonin transporter (SERT); 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the presynaptic membrane, increasing serotonin availability in the synapse. Additionally, it functions as a partial agonist at the 5-HT1A receptor, which may enhance its antidepressant efficacy compared to SSRIs alone. This dual mechanism is intended to provide faster onset of action and improved tolerability.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Diarrhea
- Dizziness
- Insomnia
- Somnolence
- Dry mouth
- Headache
Key clinical trials
- Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone (PHASE2)
- Department of Defense PTSD Adaptive Platform Trial - Master Protocol (PHASE2)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Double-Blind Treatment of Major Depressive Disorder With Vilazodone (PHASE2)
- Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (PHASE3)
- Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |